Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
TIL therapy
combination therapy
immunotherapy
solid tumor
tumor-infiltrating lymphocyte (TIL)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
08
2022
accepted:
14
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are recruited into the tumor site to fight against tumors. However, their small number and reduced activity limit their ability to overcome the tumor. Enhancement of TILs number and activity against tumors has been of interest for a long time. A lack of knowledge about the tumor microenvironment (TME) has limited success in primary TIL therapies. Although the advent of engineered T cells has revolutionized the immunotherapy methods of hematologic cancers, the heterogeneity of solid tumors warrants the application of TILs with a wide range of specificity. Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays, TIL therapy has regained attention as a safe personalized immunotherapy, and currently, several clinical trials are evaluating the efficacy of TIL therapy in patients who have failed conventional immunotherapies. Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast cancer has raised hope in patients with refractory solid tumors, too. Nevertheless, TIL therapy procedures face several challenges, such as high cost, timely expansion, and technical challenges in selecting and activating the cells. Herein, we reviewed the recent advances in the TIL therapy of solid tumors and discussed the challenges and perspectives.
Identifiants
pubmed: 36389779
doi: 10.3389/fimmu.2022.1018962
pmc: PMC9651159
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1018962Informations de copyright
Copyright © 2022 Kazemi, Sadri, Najafi, Rahimi, Baghernejadan, Khorramdelazad and Falak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Biother Radiopharm. 2001 Oct;16(5):381-90
pubmed: 11776755
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cancer Res. 2017 Jul 1;77(13):3672-3684
pubmed: 28522749
Hum Immunol. 2021 Sep;82(9):640-648
pubmed: 34119352
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Clin Cancer Res. 2016 Feb 1;22(3):680-90
pubmed: 26832745
J Clin Oncol. 2021 Aug 20;39(24):2656-2666
pubmed: 33979178
Nat Immunol. 2017 Feb 15;18(3):255-262
pubmed: 28198830
J Cell Physiol. 2018 Mar;233(3):2032-2057
pubmed: 28233320
PLoS One. 2016 Apr 06;11(4):e0153053
pubmed: 27050669
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445193
Oncoimmunology. 2018 Mar 13;7(4):e1408744
pubmed: 29632719
Gynecol Oncol. 2022 Jun;165(3):664-670
pubmed: 35400527
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
Mol Ther Oncolytics. 2020 Mar 19;17:47-60
pubmed: 32322662
Cancers (Basel). 2021 Feb 11;13(4):
pubmed: 33670139
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
Oncotarget. 2015 Dec 1;6(38):41339-49
pubmed: 26515587
Expert Opin Biol Ther. 2019 Aug;19(8):811-827
pubmed: 30986360
N Engl J Med. 1988 Dec 22;319(25):1676-80
pubmed: 3264384
Nat Biotechnol. 2013 Nov;31(11):999-1008
pubmed: 24142051
J Exp Clin Cancer Res. 2022 Apr 7;41(1):127
pubmed: 35392957
World J Surg Oncol. 2019 May 22;17(1):85
pubmed: 31118034
Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344
pubmed: 28601925
Br J Cancer. 2015 Apr 28;112(9):1510-8
pubmed: 25867267
Ann Surg Oncol. 2013 Mar;20(3):946-55
pubmed: 23010736
Oncoimmunology. 2016 Jul 1;6(9):e1207032
pubmed: 28932627
J Clin Oncol. 2019 May 10;37(14):1179-1187
pubmed: 30939091
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Dec 25;24(12):1086-1092
pubmed: 34923792
Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230
pubmed: 29845338
Anticancer Res. 2017 Aug;37(8):4587-4591
pubmed: 28739756
Nutr Rev. 1989 Jan;47(1):23-5
pubmed: 2649802
Cancer Cell Int. 2022 Aug 19;22(1):259
pubmed: 35986321
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Cancer Res. 2006 Feb 15;66(4):2442-50
pubmed: 16489051
Sci Transl Med. 2012 May 16;4(134):134ra62
pubmed: 22593175
BMC Cancer. 2015 Apr 16;15:293
pubmed: 25879689
Cancers (Basel). 2021 Nov 03;13(21):
pubmed: 34771675
Int Immunopharmacol. 2020 Jul;84:106535
pubmed: 32361569
Immunol Res. 2019 Oct;67(4-5):416-423
pubmed: 31440888
J Exp Med. 1982 Aug 1;156(2):385-97
pubmed: 6980254
Clin Cancer Res. 2013 Nov 1;19(21):5994-6005
pubmed: 24056784
Cell. 2018 Dec 13;175(7):1780-1795.e19
pubmed: 30392958
J Immunol. 2013 Oct 15;191(8):4141-51
pubmed: 24043896
Int Immunopharmacol. 2022 Jul;108:108895
pubmed: 35729831
Ther Adv Med Oncol. 2020 Aug 17;12:1758835920940928
pubmed: 32874208
Front Immunol. 2017 Nov 15;8:1564
pubmed: 29187853
Nat Commun. 2017 Nov 23;8(1):1738
pubmed: 29170503
Oncoimmunology. 2019 Aug 3;8(11):e1644108
pubmed: 31646091
PLoS One. 2016 Aug 03;11(8):e0159109
pubmed: 27487262
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Int J Biol Markers. 2019 Jun;34(2):132-138
pubmed: 30852949
Clin Cancer Res. 2010 Dec 15;16(24):6122-31
pubmed: 20668005
Oncoimmunology. 2015 Jun 3;5(2):e1054598
pubmed: 27057426
Front Immunol. 2021 Jun 01;12:690499
pubmed: 34140957
Cancer Res. 2009 Nov 1;69(21):8412-9
pubmed: 19843860
Eur J Immunol. 2015 Apr;45(4):999-1009
pubmed: 25545618
Hum Gene Ther. 2008 May;19(5):496-510
pubmed: 18444786
Gynecol Oncol. 2005 May;97(2):519-23
pubmed: 15863154
Sci Rep. 2017 Aug 8;7(1):7525
pubmed: 28790445
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Front Immunol. 2017 Aug 02;8:908
pubmed: 28824634
J Clin Lab Anal. 2021 Apr;35(4):e23725
pubmed: 33675064
J Immunother. 2010 Oct;33(8):840-7
pubmed: 20842052
Ai Zheng. 2009 Nov;28(11):1198-202
pubmed: 19895742
Front Oncol. 2018 Mar 02;8:44
pubmed: 29552542
Lancet. 1989 Mar 18;1(8638):577-80
pubmed: 2564111
J Immunother. 2007 Jan;30(1):123-9
pubmed: 17198091
Cancer. 2017 Jun 15;123(12):2219-2229
pubmed: 28346680
J Surg Oncol. 2004 Jul 15;87(1):46-52
pubmed: 15221919
J Clin Oncol. 1999 Aug;17(8):2521-9
pubmed: 10561318
Crit Rev Oncol Hematol. 2017 Feb;110:106-116
pubmed: 28109400
Curr Oncol. 2022 Jun 15;29(6):4274-4284
pubmed: 35735451
J Clin Oncol. 2022 Jun 1;40(16):1741-1754
pubmed: 35104158
Oncoimmunology. 2019 Feb 7;8(4):e1571388
pubmed: 30906667
Immunotherapy. 2020 Jun;12(9):641-652
pubmed: 32489121
Nat Immunol. 2017 Dec;18(12):1332-1341
pubmed: 29083399
Oncoimmunology. 2015 Mar 06;4(2):e976507
pubmed: 25949875
Science. 1986 Sep 19;233(4770):1318-21
pubmed: 3489291
Clin Cancer Res. 2009 Nov 1;15(21):6503-10
pubmed: 19843660
Oncol Rep. 2018 Jan;39(1):151-159
pubmed: 29138861
J Transl Med. 2012 Aug 21;10:169
pubmed: 22909342
Cancer Res. 2013 Apr 1;73(7):2127-38
pubmed: 23365136
Oncotarget. 2020 Jun 02;11(22):2092-2105
pubmed: 32547707
Int J Clin Oncol. 2010 Dec;15(6):544-51
pubmed: 20924634
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
Trends Immunol. 2009 Jul;30(7):306-12
pubmed: 19540809
PLoS One. 2012;7(2):e32639
pubmed: 22393427
Blood. 2009 Jul 16;114(3):535-46
pubmed: 19451549
Front Physiol. 2013 Aug 09;4:210
pubmed: 23950747
Ann Surg. 1922 Jan;75(1):61-9
pubmed: 17864583
Trends Immunol. 2017 Aug;38(8):577-593
pubmed: 28610825
Science. 2020 Dec 11;370(6522):1328-1334
pubmed: 33303615
Clin Cancer Res. 2007 Apr 1;13(7):2075-81
pubmed: 17404089
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
Cancer Immunol Res. 2015 Apr;3(4):326-32
pubmed: 25527356
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):553-61
pubmed: 19427557
Cancer J. 2012 Mar-Apr;18(2):160-75
pubmed: 22453018
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753545
J Neurooncol. 1999;45(2):141-57
pubmed: 10778730
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Med (N Y). 2022 Oct 14;3(10):682-704.e8
pubmed: 36007524
Curr Treat Options Oncol. 2018 Aug 13;19(9):46
pubmed: 30101402
Nat Med. 2019 Sep;25(9):1341-1355
pubmed: 31501612
Sci Rep. 2019 Dec 27;9(1):19997
pubmed: 31882709
Pediatr Blood Cancer. 2005 Nov;45(6):787-95
pubmed: 15929127
Clin Cancer Res. 2014 Jul 1;20(13):3401-10
pubmed: 24987109
Nature. 2012 Mar 25;484(7395):529-33
pubmed: 22446627
Cancers (Basel). 2019 Jan 03;11(1):
pubmed: 30609853
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Hepatology. 2013 Jul;58(1):139-49
pubmed: 22961630
Br J Cancer. 2019 Sep;121(6):490-496
pubmed: 31388183
Cell Mol Immunol. 2010 Nov;7(6):419-27
pubmed: 20871628
Oncoimmunology. 2018 Sep 26;7(12):e1502905
pubmed: 30524900
Curr Hematol Malig Rep. 2017 Dec;12(6):522-529
pubmed: 29039115
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Lancet. 2000 Sep 2;356(9232):802-7
pubmed: 11022927
Int Immunopharmacol. 2021 May;94:107461
pubmed: 33592403
Nat Med. 2021 Aug;27(8):1410-1418
pubmed: 34385708
Br J Cancer. 2003 Nov 17;89(10):1906-8
pubmed: 14612901
Nature. 2019 Jan;565(7739):366-371
pubmed: 30598548
Trends Biotechnol. 2011 Nov;29(11):550-7
pubmed: 21663987
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34607899
Virchows Arch. 2015 Oct;467(4):443-8
pubmed: 26215559
Ann Surg Oncol. 2010 Jul;17(7):1747-57
pubmed: 20119674
Prostate. 2008 Jan 1;68(1):1-10
pubmed: 17948280
Mod Pathol. 2022 May;35(5):601-608
pubmed: 34839351
JCI Insight. 2016 Jul 21;1(11):
pubmed: 27540594
Cells. 2021 Apr 22;10(5):
pubmed: 33922052
J Immunother Cancer. 2019 Mar 21;7(1):82
pubmed: 30898149
Breast Cancer. 2017 Nov;24(6):756-764
pubmed: 28429331
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e70-e78
pubmed: 31099621
J Natl Cancer Inst. 1981 Nov;67(5):997-1003
pubmed: 6457925
Int J Cancer. 2016 Sep 1;139(5):1129-39
pubmed: 27074317
J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
pubmed: 8028037
Expert Opin Biol Ther. 2022 May;22(5):627-641
pubmed: 35414331
J Urol (Paris). 1994;100(4):185-8
pubmed: 7868930
Nat Med. 2010 May;16(5):565-70, 1p following 570
pubmed: 20400962
Prostate. 2021 Jan;81(1):20-28
pubmed: 33085799
Cancer Immunol Immunother. 1987;24(1):76-85
pubmed: 3493073
J Immunol. 1999 Sep 15;163(6):2999-3006
pubmed: 10477562
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Cancer Immunol Immunother. 2015 Sep;64(9):1083-93
pubmed: 25990075
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Cancer Metastasis Rev. 2021 Jun;40(2):537-547
pubmed: 34101053
Clin Cancer Res. 2015 May 15;21(10):2278-88
pubmed: 25695689
Ann Oncol. 2019 Dec 1;30(12):1902-1913
pubmed: 31566658
J Immunol Res. 2020 Sep 07;2020:8345235
pubmed: 32964058
Cancer Immunol Immunother. 2014 Oct;63(10):1061-71
pubmed: 24993563
Ann Oncol. 2016 Mar;27(3):494-501
pubmed: 26673353
J Immunol. 2012 Jun 15;188(12):5990-6000
pubmed: 22573804
J Immunol. 2002 Aug 15;169(4):1829-36
pubmed: 12165506
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):167-177
pubmed: 35490270
Blood. 2005 Jan 1;105(1):241-50
pubmed: 15345595
Cytotherapy. 2019 Mar;21(3):307-314
pubmed: 30509772
Breast Cancer Res Treat. 2018 Sep;171(2):273-282
pubmed: 29858752
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34301811
Haematologica. 2005 Oct;90(10):1365-72
pubmed: 16219573
Mol Ther. 2022 Jun 17;:
pubmed: 35715953
Br J Cancer. 2004 Aug 2;91(3):541-3
pubmed: 15266325
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668519
Cell Res. 2017 Apr;27(4):461-482
pubmed: 28290464
Int Immunopharmacol. 2021 Sep;98:107886
pubmed: 34153663
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483
Mol Ther Oncolytics. 2022 Jan 10;24:417-428
pubmed: 35141398
Clin Cancer Res. 2019 Mar 1;25(5):1486-1493
pubmed: 30518633
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Oncoimmunology. 2020 May 22;9(1):1761229
pubmed: 32923123
Am J Clin Pathol. 2009 Apr;131(4):498-510
pubmed: 19289585
J Pathol. 2010 Dec;222(4):350-66
pubmed: 20927778
Hematol Oncol Stem Cell Ther. 2014 Mar;7(1):1-17
pubmed: 24398144
Cancer Immunol Immunother. 2021 Feb;70(2):509-518
pubmed: 32845355
Cancer J. 2015 Nov-Dec;21(6):450-64
pubmed: 26588676
Clin Cancer Res. 2020 May 15;26(10):2284-2289
pubmed: 32001481
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11510-6
pubmed: 26617883
World J Urol. 2016 Feb;34(2):181-7
pubmed: 26055646
Blood. 2010 Nov 11;116(19):3853-64
pubmed: 20696944
Br J Cancer. 2013 Oct 1;109(7):1839-47
pubmed: 24008661
Genet Mol Res. 2016 Sep 9;15(3):
pubmed: 27706714
Melanoma Res. 2018 Jun;28(3):171-184
pubmed: 29521881
J Clin Invest. 2013 Oct;123(10):4479-88
pubmed: 24091329
J Transl Med. 2008 May 16;6:25
pubmed: 18485193
Clin Dev Immunol. 2010;2010:260267
pubmed: 21234353
Cancer Res. 1991 Apr 1;51(7):1934-9
pubmed: 2004379
Cancer Gene Ther. 2021 Feb;28(1-2):98-111
pubmed: 32632271
Eur J Cancer. 2016 Jun;60:1-11
pubmed: 27038842
BioDrugs. 2014 Oct;28(5):421-37
pubmed: 24890028
Cell. 2016 Sep 8;166(6):1500-1511.e9
pubmed: 27610572
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
J Immunol Res. 2020 Oct 01;2020:7890985
pubmed: 33062726
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Nat Rev Cancer. 2021 Jun;21(6):341
pubmed: 33864034
Biomed Pharmacother. 2022 Feb;146:112512
pubmed: 34894519
Clin Cancer Res. 1995 May;1(5):501-7
pubmed: 9816009
Life Sci. 2019 Aug 15;231:116543
pubmed: 31176775
J Transl Med. 2011 Aug 09;9:131
pubmed: 21827675
Oncoimmunology. 2020 Jul 11;9(1):1792058
pubmed: 32923156
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
J Clin Oncol. 1988 May;6(5):839-53
pubmed: 3259261
Nat Med. 2019 Oct;25(10):1488-1499
pubmed: 31591590
Front Immunol. 2021 Oct 04;12:765101
pubmed: 34675942
Clin Cancer Res. 2000 Jun;6(6):2268-78
pubmed: 10873077
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
J Urol. 1997 Sep;158(3 Pt 1):740-5
pubmed: 9258071
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Cancer. 2010 Nov 15;116(22):5188-99
pubmed: 20665489
BMC Med. 2021 Jun 11;19(1):140
pubmed: 34112147